

What is She Waiting For?



Accurate Results Personalized Diagnosis

Correct Treatment

Precipio's Mission Is To Eradicate Cancer Misdiagnosis



Here's the problem...

1 in 4 Blood Cancer Patients Are Misdiagnosed or Misclassified...




Due to Inaccuracies in **Initial Suspicions...**40% of Precipio's cases arrive at a diagnosis that is different than the initial clinical suspicion. ²



Derived from the **Ever Expanding, Complex List** of Blood Cancer Subtypes...

205 blood cancer subtypes ³



Resulting in **Incorrect Treatments** and **Delays** in critical care. Every month in delayed treatment can raise risk of death by ~10% ⁴



- 1: National Coalition on Healthcare, 2013
- 2: Precipio internal clinical laboratory data
- 3: Swenslow, Steven H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition ed., Lyon, 2017
- 4: https://www.bmj.com/company/newsroom/every-month-delayed-in-cancer-treatment-can-raise-risk-of-death-by-around-10/



Precipio's Mission Is To Eradicate Cancer Misdiagnosis



Here's how we solve it...with Omnia


Relevant patient data is compiled for a complete understanding of patient status

Clinical Suspicion


Clinical History

Past Testing

Recent CBC



2. Each patient sample is **skillfully triaged** by our **Hematopathology** team based on the latest **WHO guidelines**



- Efficient sample triage in 1 lab location
- Same day acute process identificationIncluding pathologist consultation
- Only medically necessary testing
- Comprehensive testing & reporting



Expert Hematopathologists are available for consultation with you throughout the diagnostic process to ensure, together, we get to the right answers for your patients.

Precipio's Mission Is To Eradicate Cancer Misdiagnosis



Proprietary **Sample Preparation** & **Molecular Technologies** deliver comprehensive accurate diagnoses.



Cell Enrichment Technology

For low cellularity samples (<5% plasma cells) for more conclusive FISH results



Conclusive FISH results >95% of cases

- 1. Low cellularity sample received
- 2. Cell selectively enriched using magnetic beads
- 3. Rev-CI process removes magnetic beads
- 4. FISH testing conducted
- 5. Conclusive FISH results achieved



Universal Cytogenetic Medium

Cultures All 4 cell lineages simultaneously to reduce False Negatives



Simultaneous 4 cell line culturing

Myeloid

B-Cell

T-Cell

Plasma



Comprehensive Molecular Panels

For deeper clinical insight



Rapid driver mutation panel testing

MPN

AML

BCR-ABL1

CLL

Cytopenia

See the real world impact our technologies have on patients in our **Case Studies**:



